Prophylactic therapy with human amniotic fluid stem cells improved survival in a rat model of lipopolysaccharide-induced neonatal sepsis through immunomodulation via aggregates with peritoneal macrophages.
Human amniotic fluid stem cells
Immunomodulation
Inflammatory cytokines
Macrophage polarization
Mesenchymal stem cells
Neonatal sepsis
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
20 07 2020
20 07 2020
Historique:
received:
03
04
2020
accepted:
03
07
2020
revised:
06
06
2020
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Despite recent advances in neonatal care, sepsis remains a leading cause of mortality in neonates. Mesenchymal stem cells derived from various tissues, such as bone marrow, umbilical cord, and adipose tissue, have beneficial effects on adult sepsis. Although human amniotic fluid stem cells (hAFSCs) have mesenchymal stem cell properties, the efficacy of hAFSCs on neonatal sepsis is yet to be elucidated. This study aimed to investigate the therapeutic potential of hAFSCs on neonatal sepsis using a rat model of lipopolysaccharide (LPS)-induced sepsis. hAFSCs were isolated as CD117-positive cells from human amniotic fluid. Three-day-old rat pups were intraperitoneally treated with LPS to mimic neonatal sepsis. hAFSCs were administered either 3 h before or at 0, 3, or 24 h after LPS exposure. Serum inflammatory cytokine levels, gene expression profiles from spleens, and multiple organ damage were analyzed. hAFSC localization was determined in vivo. In vitro LPS stimulation tests were performed using neonatal rat peritoneal macrophages co-cultured with hAFSCs in a cell-cell contact-dependent/independent manner. Immunoregulation in the spleen was determined using a DNA microarray analysis. Prophylactic therapy with hAFSCs improved survival in the LPS-treated rats while the hAFSCs transplantation after LPS exposure did not elicit a therapeutic response. Therefore, hAFSC pretreatment was used for all subsequent studies. Inflammatory cytokine levels were elevated after LPS injection, which was attenuated by hAFSC pretreatment. Subsequently, inflammation-induced damages in the brain, lungs, and liver were ameliorated. hAFSCs aggregated with peritoneal macrophages and/or transiently accumulated in the liver, mesentery, and peritoneum. Paracrine factors released by hAFSCs induced M1-M2 macrophage polarization in a cell-cell contact-independent manner. Direct contact between hAFSCs and peritoneal macrophages further enhanced the polarization. Microarray analysis of the spleen showed that hAFSC pretreatment reduced the expression of genes involved in apoptosis and inflammation and subsequently suppressed toll-like receptor 4 signaling pathways. Prophylactic therapy with hAFSCs improved survival in a rat model of LPS-induced neonatal sepsis. These effects might be mediated by a phenotypic switch from M1 to M2 in peritoneal macrophages, triggered by hAFSCs in a cell-cell contact-dependent/independent manner and the subsequent immunomodulation of the spleen.
Sections du résumé
BACKGROUND
Despite recent advances in neonatal care, sepsis remains a leading cause of mortality in neonates. Mesenchymal stem cells derived from various tissues, such as bone marrow, umbilical cord, and adipose tissue, have beneficial effects on adult sepsis. Although human amniotic fluid stem cells (hAFSCs) have mesenchymal stem cell properties, the efficacy of hAFSCs on neonatal sepsis is yet to be elucidated. This study aimed to investigate the therapeutic potential of hAFSCs on neonatal sepsis using a rat model of lipopolysaccharide (LPS)-induced sepsis.
METHODS
hAFSCs were isolated as CD117-positive cells from human amniotic fluid. Three-day-old rat pups were intraperitoneally treated with LPS to mimic neonatal sepsis. hAFSCs were administered either 3 h before or at 0, 3, or 24 h after LPS exposure. Serum inflammatory cytokine levels, gene expression profiles from spleens, and multiple organ damage were analyzed. hAFSC localization was determined in vivo. In vitro LPS stimulation tests were performed using neonatal rat peritoneal macrophages co-cultured with hAFSCs in a cell-cell contact-dependent/independent manner. Immunoregulation in the spleen was determined using a DNA microarray analysis.
RESULTS
Prophylactic therapy with hAFSCs improved survival in the LPS-treated rats while the hAFSCs transplantation after LPS exposure did not elicit a therapeutic response. Therefore, hAFSC pretreatment was used for all subsequent studies. Inflammatory cytokine levels were elevated after LPS injection, which was attenuated by hAFSC pretreatment. Subsequently, inflammation-induced damages in the brain, lungs, and liver were ameliorated. hAFSCs aggregated with peritoneal macrophages and/or transiently accumulated in the liver, mesentery, and peritoneum. Paracrine factors released by hAFSCs induced M1-M2 macrophage polarization in a cell-cell contact-independent manner. Direct contact between hAFSCs and peritoneal macrophages further enhanced the polarization. Microarray analysis of the spleen showed that hAFSC pretreatment reduced the expression of genes involved in apoptosis and inflammation and subsequently suppressed toll-like receptor 4 signaling pathways.
CONCLUSIONS
Prophylactic therapy with hAFSCs improved survival in a rat model of LPS-induced neonatal sepsis. These effects might be mediated by a phenotypic switch from M1 to M2 in peritoneal macrophages, triggered by hAFSCs in a cell-cell contact-dependent/independent manner and the subsequent immunomodulation of the spleen.
Identifiants
pubmed: 32690106
doi: 10.1186/s13287-020-01809-1
pii: 10.1186/s13287-020-01809-1
pmc: PMC7370504
doi:
Substances chimiques
Lipopolysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
300Références
Stem Cell Res Ther. 2018 Apr 6;9(1):91
pubmed: 29625582
PLoS One. 2010 Feb 16;5(2):e9252
pubmed: 20169081
Pediatr Res. 2019 Jan;85(1):97-104
pubmed: 30120407
Front Pediatr. 2018 Jul 19;6:199
pubmed: 30073156
Mol Med Rep. 2016 Oct;14(4):3862-70
pubmed: 27600821
Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L1068-78
pubmed: 16829629
Keio J Med. 2018 Dec 26;67(4):57-66
pubmed: 29515049
Nat Rev Immunol. 2008 Oct;8(10):776-87
pubmed: 18802444
Am J Respir Cell Mol Biol. 2016 Dec;55(6):767-778
pubmed: 27438994
Stem Cells Transl Med. 2016 Aug;5(8):1048-57
pubmed: 27280799
Gut. 2014 Feb;63(2):218-9
pubmed: 23616579
Stem Cells. 2017 Dec;35(12):2331-2339
pubmed: 28856759
J Immunol. 2009 Dec 1;183(11):7150-60
pubmed: 19917677
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13724-9
pubmed: 20643923
Stem Cells Dev. 2017 Jul 15;26(14):1054-1064
pubmed: 28401804
Exp Neurol. 2016 May;279:283-289
pubmed: 26953231
J Exp Med. 2006 Jul 10;203(7):1637-42
pubmed: 16818669
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S29-52
pubmed: 26428501
Pediatr Pulmonol. 2013 Nov;48(11):1070-80
pubmed: 23533160
World J Stem Cells. 2015 Mar 26;7(2):368-79
pubmed: 25815121
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1047-57
pubmed: 20558630
Mol Ther. 2010 Oct;18(10):1857-64
pubmed: 20664529
Hum Cell. 2019 Jan;32(1):51-63
pubmed: 30506493
Pediatr Res. 2018 Jul;84(1):139-145
pubmed: 29795214
Stem Cell Res Ther. 2019 Nov 15;10(1):320
pubmed: 31730019
Gastroenterology. 2015 Jul;149(1):163-176.e20
pubmed: 25790743
Stem Cell Res Ther. 2019 Oct 17;10(1):301
pubmed: 31623677
Shock. 2017 Feb;47(2):242-250
pubmed: 27454382
Cell Transplant. 2010;19(6):823-30
pubmed: 20573305
J Immunol. 2007 Aug 1;179(3):1855-63
pubmed: 17641052
Nat Biotechnol. 2007 Jan;25(1):100-6
pubmed: 17206138
Stem Cells Transl Med. 2019 Nov;8(11):1170-1179
pubmed: 31407874
Front Neurol. 2018 Sep 11;9:757
pubmed: 30254603
Stem Cell Res Ther. 2016 Feb 10;7:27
pubmed: 26864573
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
Lancet. 2017 Oct 14;390(10104):1770-1780
pubmed: 28434651
Sci Rep. 2018 Feb 5;8(1):2425
pubmed: 29402914
BMC Pulm Med. 2019 Nov 9;19(1):206
pubmed: 31706309
Stem Cells. 2017 Jul;35(7):1663-1673
pubmed: 28009066
Nat Med. 2009 Jan;15(1):42-9
pubmed: 19098906
Organogenesis. 2012 Jul-Sep;8(3):77-88
pubmed: 23037870
J Immunol. 2014 Apr 1;192(7):3156-65
pubmed: 24591376
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7528-33
pubmed: 18490660
Eur J Immunol. 2015 Jan;45(1):214-24
pubmed: 25329762
Brain Behav Immun. 2017 Feb;60:220-232
pubmed: 27847282
Am J Respir Crit Care Med. 2018 Feb 1;197(3):337-347
pubmed: 28960096
Stem Cells. 2014 Jul;32(7):1865-77
pubmed: 24496748
Stem Cells. 2013 Nov;31(11):2443-56
pubmed: 23922312
Stem Cells. 2018 Nov;36(11):1778-1788
pubmed: 30063804
Am J Physiol Regul Integr Comp Physiol. 2011 Jun;300(6):R1506-14
pubmed: 21451141
Clin Perinatol. 2010 Jun;37(2):307-37
pubmed: 20569810